[{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||HDAC","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Kathmandu University","sponsor":"Asian Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Neurology","graph2":"Phase IV","graph3":"Kathmandu University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Kathmandu University \/ Asian Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Kathmandu University \/ Asian Pharmaceuticals"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"BioPharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Desitin Arzneimittel \/ BioPharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Desitin Arzneimittel \/ BioPharma Services"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Syneos Health | Nuventra","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||DRD1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Syneos Health | Nuventra","highestDevelopmentStatusID":"6","companyTruncated":"Emalex Bioscience \/ Syneos Health | Nuventra"},{"orgOrder":0,"company":"Westat","sponsor":"US Department of Defense | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Westat \/ US Department of Defense | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ US Department of Defense | Clinipace Worldwide"},{"orgOrder":0,"company":"Westat","sponsor":"US Department of Defense | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Westat \/ US Department of Defense | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ US Department of Defense | Clinipace Worldwide"},{"orgOrder":0,"company":"Centre d'Etude des Cellules Souches","sponsor":"Genethon","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Centre d'Etude des Cellules Souches","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre d'Etude des Cellules Souches \/ Genethon","highestDevelopmentStatusID":"8","companyTruncated":"Centre d'Etude des Cellules Souches \/ Genethon"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||HDAC","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerebral Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cerebral Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mefenamic Acid","moa":"||Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Undisclosed","graph2":"Phase I","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||HDAC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cereno Scientific \/ Inapplicable"},{"orgOrder":0,"company":"University of Twente","sponsor":"H\u00f4pital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lorazepam","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Twente","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Twente \/ H\u00f4pital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre","highestDevelopmentStatusID":"1","companyTruncated":"University of Twente \/ H\u00f4pital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre"}]
Find Clinical Drug Pipeline Developments & Deals for Depakine
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
